超声内镜引导下紫杉醇注射作为局部或区域食管癌术前全身化疗和同步外照射放疗的辅助治疗:一项多中心前瞻性随机试验
这项国际多中心前瞻性随机2b期试验纳入137例适合新辅助放化疗的局部或区域食管/胃食管交界腺癌或鳞癌患者,随机接受标准治疗联合超声内镜引导下紫杉醇注射或单纯标准治疗。联合组与单纯标准治疗组的总体肿瘤体积反应率相似(12.5% vs 20.0%,P=0.24),病理完全缓解率在单纯标准治疗组更高(26.2% vs 12.5%,P=0.046),12个月生存率和不良事件总频率两组相似。结论认为联合紫杉醇注射安全但未改善总生存或原发肿瘤总体反应。
要点
- 联合组与单纯标准治疗组的总体肿瘤体积反应率相似(12.5% vs 20.0%,P=0.24)。
- 病理完全缓解率在单纯标准治疗组更高(26.2% vs 12.5%,P=0.046)。
- 两组12个月生存率和不良事件总频率相似。
核心结论
- 标准治疗联合超声内镜引导下紫杉醇注射安全,但未改善局部或区域食管/胃食管交界癌患者的总生存或原发肿瘤部位的总体肿瘤反应。
研究设计与样本
- 国际多中心、前瞻性、随机2b期研究,纳入适合术前新辅助放化疗的局部或区域食管/胃食管交界腺癌或鳞癌患者,随机分至标准治疗联合超声内镜引导下紫杉醇注射组(n=72)或单纯标准治疗组(n=65),采用改良意向性治疗分析,共分析137例(97例男性;平均年龄58±9.1岁)。
主要发现
- 联合组与单纯标准治疗组的总体肿瘤体积反应率相似(12.5% vs 20.0%;P=0.24;比值比0.57;95%置信区间0.23-1.44)。
- 病理完全缓解率在单纯标准治疗组更高(26.2% vs 12.5%;P=0.046)。
- 两组12个月生存率(P=0.412)和发生1种或以上不良事件的总体频率(P=0.17)相似。
关键数值与推荐
- 紫杉醇以0.5至1.0 mL等分注射至整个肿瘤。
- 计划的标准治疗放化疗为:第1周和第5周前4天静脉给予5-氟尿嘧啶,每个5-氟尿嘧啶疗程第1天静脉给予顺铂,放疗持续5.5周。
- 放化疗期间每周评估,12周时重新评估手术资格并通过CT评估总体肿瘤体积变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: OncoGel (Protherics Salt Lake City, Inc, Salt Lake City, UT) is paclitaxel (PTX) formulated in a thermosensitive, biodegradable copolymer for focused cytotoxicity and radiosensitization. A phase 2a study suggested that EUS-guided PTX injection into esophageal tumors subsequently receiving radiotherapy was safe. METHODS: In an international multicenter, prospective, randomized phase 2b study, patients with local or locoregional adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus/gastroesophageal junction and eligible for neoadjuvant chemoradiotherapy (CRT) before surgery were randomized to standard of care (SOC) plus EUS-guided PTX injection or SOC alone. PTX was injected in 0.5 to 1.0 mL aliquots throughout the tumor. Planned CRT as SOC was intravenous 5-fluorouracil for the first 4 days (weeks 1 and 5), intravenous cisplatin on the first day of each 5-fluorouracil course, and radiotherapy over 5.5 weeks. Patients were evaluated weekly during CRT and re-evaluated at 12 weeks for surgical eligibility and CT for change in overall tumor volume. RESULTS: The analysis included 137 patients (97 males; mean age, 58 ± 9.1 years) randomized to PTX + SOC (n = 72) and SOC (n = 65) by using a modified intention-to-treat approach. Overall response by tumor volume between the PTX (12.5%) and the SOC group (20.0%; P = .24; odds ratio, 0.57; 95% confidence interval, 0.23-1.44) was similar. Pathologic complete response was higher in the SOC group (26.2% vs 12.5%; P = .046); however, 12-month survival (P = .412) and the overall frequency of 1 or more adverse events (P = .17) were similar between the 2 groups. CONCLUSIONS: SOC + PTX is safe but does not improve overall survival or overall tumor response at the primary tumor site for patients with local or locoregional cancer of the esophagus/gastroesophageal junction. (Clinical trial registration number: NCT00573131.).
引用
- DeWitt JM, Murthy SK, Ardhanari R, et al. EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial. Gastrointest Endosc. 2016. PMID: 27890801. doi:10.1016/j.gie.2016.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。